Procter & Gamble's 10-Q for the quarter ended September 30, 2026 (fiscal Q1 2027) shows the pattern a value investor expects from a mature consumer staples franchise: a top line that grew, an operating line that barely moved, and a gross margin that gave ground. Revenue rose about 4%. Operating income rose about 1%. Operating margin slipped roughly 65 basis points. The useful question is not whether the quarter was good or bad in isolation, but what the mix of price, cost and overhead says about the durability of the margin structure.
The quarter against the year-earlier period
| Line item (USD) | Q1 FY27 (Sep-26) | Q1 FY26 (Sep-25) | Change |
|---|---|---|---|
| Revenue | $23.28B | $22.39B | +4.0% |
| Cost of goods sold | $11.68B | $10.89B | +7.3% |
| Gross margin (derived) | 49.8% | 51.4% | -154 bps |
| SG&A | $5.66B | $5.64B | +0.3% |
| SG&A as % of revenue (derived) | 24.3% | 25.2% | -89 bps |
| Operating income | $5.94B | $5.86B | +1.4% |
| Operating margin (derived) | 25.5% | 26.2% | -65 bps |
| Net income | $4.73B | $4.75B | -0.4% |
| Diluted EPS | $1.97 | $1.95 | +1.0% |
| Basic EPS | $2.00 | $2.00 | flat |
| Diluted weighted shares | 2,407M | 2,437M | -1.2% |
Two details matter here. First, describing operating income as "about $5.9B versus about $5.9B" is accurate to rounding but hides a 1.4% gain. Second, the net income line went slightly backward while operating income rose. Based on the filed lines, the gap sits below the operating line: interest expense rose to about $223M from about $197M, other non-operating income fell to about $207M from about $268M, and income tax expense rose to about $1.27B from about $1.25B. The share count fell about 1.2%, which is why diluted EPS still edged up about 1% even though net income did not.
Revenue growth is real but not a straight line
The roughly 4% top-line gain is in line with the prior year's pattern, but the quarterly path is uneven. Year-over-year revenue growth by quarter, derived from the reported quarterly figures, is shown below alongside the margins that went with each quarter.
| Quarter | Revenue YoY (derived) | Gross margin (derived) | Operating margin (derived) |
|---|---|---|---|
| Q1 FY26 | +3.0% | 51.4% | 26.2% |
| Q2 FY26 | +1.5% | 51.2% | 24.2% |
| Q3 FY26 | +7.4% | 49.5% | 21.5% |
| Q4 FY26 | +1.5% | 48.5% | 18.6% |
| Q1 FY27 | +4.0% | 49.8% | 25.5% |
The Q3 FY26 spike reflects a weak comparison base (Q3 FY25 revenue was the lowest in the series shown), so the 7.4% figure should not be read as a trend. Excluding that quarter, growth has run between roughly 1.5% and 3% a quarter. The FY2026 MD&A summary attributes most of the full-year gain to foreign exchange (about 2 points) and pricing (about 1 point), with unit volume and mix unchanged and organic sales up about 1%. The available data does not include the Q1 FY27 MD&A, so I cannot say how much of this quarter's 4% came from currency versus pricing or volume. That is the single most important missing input for judging the top line.
Where the 65 basis points went
Gross margin fell about 154 basis points, and cost of goods sold grew about 7.3% against revenue growth of about 4%. That is the pressure point. Below gross profit, SG&A grew only 0.3%, which fell to about 24.3% of sales from 25.2%. That leverage recovered about 89 basis points, leaving a net operating margin decline of about 65 basis points.
This is the core tension in the quarter. Management's overhead discipline is visible: the company has a two-year plan to cut up to 7,000 overhead roles by fiscal 2027, and the FY2026 MD&A cites $903 million of after-tax restructuring charges. Those cuts are the likely source of the SG&A leverage. But the gross margin line is where a staples franchise shows whether its brands can pass through input-cost inflation. The FY2026 MD&A describes gross margin falling 100 basis points to 50.2% on unfavorable product mix, product and packaging investment and higher restructuring costs, partly offset by manufacturing productivity. The reported data does not state what drove the Q1 FY27 COGS increase, and I would not assume it was the same mix.
The margin path is also worth placing against the prior year. Operating margin was 26.7% in Q1 FY25, 26.2% in Q1 FY26 and 25.5% in Q1 FY27. Across the intervening quarters it fell much further, to 18.6% in Q4 FY26, before recovering sequentially this quarter. The full-year FY2026 operating margin of 22.7% was about 160 basis points below FY2025. Whether Q1 FY27 marks a floor or a pause is not something one quarter can establish.
Balance sheet and capital items in view
The FY2026 MD&A reports operating cash flow of $19.6 billion and adjusted free cash flow of $15.8 billion, with current liabilities exceeding current assets by $12.5 billion, $8.0 billion of undrawn credit facilities, and total contractual commitments of $45.8 billion including $34.5 billion of debt. Credit ratings are stated as stable (Aa3/AA-). A pending $3.8 billion acquisition of Thorne is expected to close in fiscal Q2 2027. None of these items is visible in the Q1 income statement, but each bears on how much of future operating income is available for dividends, buybacks and debt service versus reinvestment.
Valuation context, without a verdict
The computed key metrics place PG at roughly 25x earnings, about 17.7x EV/EBITDA, a dividend yield near 2.6% and a free cash flow yield near 4.0%. The reader's question is not whether those multiples are high or low on their own; it is which margin path they require. A holder who expects operating margin to recover toward the mid-20s seen in early FY2025 is underwriting a different outcome from one who expects the FY2026 compression to persist, and both views can be tested against the next few quarters of gross margin and SG&A ratio. We are describing that sensitivity, not drawing a conclusion from it.